Company / SG&A Expense
Olema Pharmaceuticals, Inc. SG&A Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$17.7M
FY2024
5-year range
$7.8M / $24.7M
FY2020-FY2024
Trend
-5.7%
vs FY2023
Sector context
#202 of 213
Health Care
What the data says
Among 213 Health Care companies, Olema Pharmaceuticals, Inc. is in the top 5% for sg&a expense. Improved from $25M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2024 with a 5-year CAGR of +113.2%.
Improved from $25M to $18M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -4.5%
- 5-Year CAGR
- +113.2%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 213This company $17.7M Sector average $722.3M
▼
-97.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +113.2%, indicating consistent growth.
- In FY2024, sg&a expense decreased 5.7% year-over-year.
- Ranks #202 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $17.7M | -5.7% |
| FY2023 | $18.8M | -23.8% |
| FY2022 | $24.7M | +21.2% |
| FY2021 | $20.4M | +160.6% |
| FY2020 | $7.8M | +1841.4% |
| FY2019 | $403.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026